Adalimumab demonstrated the highest persistence, while infliximab exhibited the lowest retention rate in AS, although this trend did not reach statistical significance [ 8 ].
← all excerpts
Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study.
1
—
—